76
|
Matsui T, Kono T, Hata T, Fukunaga M, Munemoto Y, Nagata N, Shimada M, Morita S, Sakamoto J, Mishima H. 6089 POSTER Goshajinkigan (TJ-107) for Oxaliplatin-induced Sensory Neurotoxicity in Colorectal Cancer Patients – a Prospective, Randomized, Double-blinded, Placebo-controlled, Phase II Trial (GONE). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71734-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
77
|
Ishibashi K, Koda K, Oshiro M, Matsuoka H, Baba H, Ishida H, Katoh R, Maeda K, Hamada C, Sakamoto J. 6098 POSTER CRAFT Trial-Result From Multicenter Phase II Study of Modified FOLFOX7 (Combination Chemotherapy of Infusional 5-FU/l-Leucovorin and Intermittent Oxaliplatin) With Bevacizumab in the First-line Therapy of Colorectal Cancer. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71743-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
78
|
Ravel J, Brotman R, Gajer P, Sakamoto J, Koenig S, Fu L, Zhou X, Abdo Z, Forney L, Ravel J. P4-S4.04 Temporal dynamics of vaginal bacterial communities. Br J Vener Dis 2011. [DOI: 10.1136/sextrans-2011-050108.529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
79
|
Brotman R, Jones LL, Sakamoto J, Gajer P, Ault K, Peralta L, Forney L, Abdo Z, Ravel J. O1-S05.05 Association between Trichomonas vaginalis and vaginal bacterial community composition among asymptomatic reproductive-age women in the USA. Br J Vener Dis 2011. [DOI: 10.1136/sextrans-2011-050109.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
80
|
Matsui T, Kono T, Hata T, Munemoto Y, Fukunaga M, Nagata N, Nishioka M, Hasegawa J, Kunieda K, Morita S, Sakamoto J, Mishima H. Neuroprotective effects of goshajinkigan (TJ-107) in colorectal cancer patients receiving oxaliplatin-based chemotherapy: A double-blind, placebo-controlled, randomized phase II trial from the GONE Study Group. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
81
|
Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Miyashita Y, Morita S, Oba K, Buyse ME, Macdonald JS, Sakamoto J. SAMIT: Preliminary safety data from a 2x2 factorial randomized phase III trial to investigate weekly paclitaxel (PTX) followed by oral fluoropyrimidines (FPs) versus FPs alone as adjuvant chemotherapy in patients (pts) with gastric cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4017] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
82
|
Sakamoto J, Yamada T, Chen F, Nakajima D, Ohsumi A, Fujinaga T, Shoji T, Sakai H, Bando T, Date H. 424 Protective Effect of Ventilation before Organ Procurement on Graft Lungs Donated after Cardiac Death in a Canine Lung Transplantation Model. J Heart Lung Transplant 2011. [DOI: 10.1016/j.healun.2011.01.433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
83
|
Nakajima D, Yamada T, Chen F, Sakamoto J, Ohsumi A, Fujinaga T, Shoji T, Sakai H, Bando T, Date H. 91 Reconditioning of Lungs from Non-Heart-Beating Donors with Normothermic Ex Vivo Lung Perfusion. J Heart Lung Transplant 2011. [DOI: 10.1016/j.healun.2011.01.098] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
84
|
Yamada T, Nakajima D, Sakamoto J, Chen F, Okamoto T, Ohsumi A, Fujinaga T, Shoji T, Sakai H, Bando T, Date H. 422 Reconditioning of Lungs with Pulmonary Edema in Ex Vivo Lung Perfusion Circuit. J Heart Lung Transplant 2011. [DOI: 10.1016/j.healun.2011.01.431] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
85
|
Dao HH, Do QT, Sakamoto J. Abnormal body composition phenotypes in Vietnamese women with early rheumatoid arthritis. Rheumatology (Oxford) 2011; 50:1250-8. [DOI: 10.1093/rheumatology/ker004] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
|
86
|
Takahashi T, Yoshida K, Hamada C, Sakamoto J, Satoh T, Sadahiro S, Mishima H, Watanabe M, Sugihara K, Tomita N. Six months compared with 12 months of capecitabine as adjuvant chemotherapy for stage III (Dukes' C) colon cancer: Rationale for the open-label randomized phase III study, JFMC37-0801. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
517 Background: The standard duration of adjuvant chemotherapy (CT) in patient with stage III colorectal cancer is 6 months. On the other hand, no clinical trial which investigate an optimal duration of oral chemotherapeutic agents has yet been implemented for adjuvant treatments. According to the ACCENT database (Sargent, et al. J Clin Oncol 27: 872- 877, 2009), 83% of recurrences in stage II and III pts have occurred within the first 3 years after surgery and peak was observed around one year after surgery. Also, single-agent FU-based adjuvant CT reduced the hazard rate of OS, DFS, and TTR, although the peak of events around one year was still remained especially for stage III pts. We analyzed the data of recurrent risk of curatively resected colon cancer pts provided by JFMC7-1-7-2-15, X-ACT. Surgery alone group and 6 months CT (5FU/LV or capecitabine [Cape]) showed highest peak between 12 months to 18 months after surgery, but 12 months oral 5-FUs group did not show recurrence peak between 12 months to 18 months after surgery. Therefore, to clarify the benefit of 12 month administration of Cape, we planned a phase III randomized trial for a comparison of 6 months treatment and 12 months treatment. Methods: JFMC37 is a multicenter, randomized phase III trial. Patients with fully resected stage III colon or recto sigmoid cancer were eligible. Patients were randomized 1:1 to receive Cape of 6 months (arm A) or Cape of 12 months (arm B). Primary endpoint is disease-free survival. The statistical design is based on superiority hypothesis; 5-yrs DFS is 60% in arm A, 67% in arm B; unilateral α=0.05, 1-β=0.8; and planed accrual is 1200 pts. Results: Between September 2008 to December 2009, 1,304 pts were randomized. Patients characteristics are (armA/armB); number 653/651, gender M352-F301/M343-F308, median age 65 years/65 years, ECOG PS=0-1 620-33/632-19, involvement of lymph nodes=N0-N1-N2 503-130-20/499-128-24. There were no differences in baseline characteristics between arm A and arm B. Conclusions: This trial is expected to show if 1 year adjutant chemotherapy with capecitabine can reduce the peak of recurrence in 1 year and provide long-term OS benefit. [Table: see text]
Collapse
|
87
|
Dao HH, Harun-Or-Rashid M, Sakamoto J. Body composition and metabolic syndrome in patients with primary gout in Vietnam. Rheumatology (Oxford) 2010; 49:2400-7. [DOI: 10.1093/rheumatology/keq274] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
88
|
Watanabe S, Sakamoto J, Wakita M. Pigeons' discrimination of paintings by Monet and Picasso. J Exp Anal Behav 2010; 63:165-74. [PMID: 16812755 PMCID: PMC1334394 DOI: 10.1901/jeab.1995.63-165] [Citation(s) in RCA: 117] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Pigeons successfully learned to discriminate color slides of paintings by Monet and Picasso. Following this training, they discriminated novel paintings by Monet and Picasso that had never been presented during the discrimination training. Furthermore, they showed generalization from Monet's to Cezanne's and Renoir's paintings or from Picasso's to Braque's and Matisse's paintings. These results suggest that pigeons' behavior can be controlled by complex visual stimuli in ways that suggest categorization. Upside-down images of Monet's paintings disrupted the discrimination, whereas inverted images of Picasso's did not. This result may indicate that the pigeons' behavior was controlled by objects depicted in impressionists' paintings but was not controlled by objects in cubists' paintings.
Collapse
|
89
|
Miyatake T, Enomoto T, Oka Y, Nishida S, Tsuboi A, Shirakata T, Morita S, Sakamoto J, Sugiyama H, Kimura T. Clinical trials of WT1 peptide vaccine to gynecologic malignancies that are resistant to conventional therapies. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
90
|
Yoshikawa T, Tsuburaya A, Morita S, Kodera Y, Ito S, Cho H, Miyashita Y, Sakamoto J. A Comparison of Multimodality Treatment: Two or Four Courses of Paclitaxel plus Cisplatin or S-1 plus Cisplatin Followed by Surgery for Locally Advanced Gastric Cancer, a Randomized Phase II Trial (COMPASS). Jpn J Clin Oncol 2010; 40:369-372. [DOI: 10.1093/jjco/hyp178] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
91
|
Hirata M, Takao S, Okamoto Y, Yamashita S, Kawaguchi Y, Takami M, Furusawa H, Abe C, Sakamoto J, Yoshimoto M. 472 A phase II trial of oral combination chemotherapy with capecitabine and cyclophosphamide (XC) in metastatic breast cancer. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70493-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
92
|
Yamamoto D, Taguchi T, Masuda N, Nakayama T, Nagata T, Nomura M, Yoshidome K, Yoshino H, Sakamoto J, Noguchi S. 484 Impact of 4-weekly capecitabine plus paclitaxel (XP) combination therapy for metastatic breast cancer: a multicenter phase II trial (KBCSG-0609). EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70505-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
93
|
Yamada T, Chen F, Sakamoto J, Nakajima D, Satoda N, Takahashi A, Fujinaga T, Shoji T, Sakai H, Bando T. 509: Injury of Donor Lungs from Donation after Cardiac Death in Various Settings; Investigation by RT-PCR and Pathology. J Heart Lung Transplant 2010. [DOI: 10.1016/j.healun.2009.11.526] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
94
|
Sakamoto J, Kosaka S, Hijiya K. [Bronchogenic cyst with a high computed tomography number]. KYOBU GEKA. THE JAPANESE JOURNAL OF THORACIC SURGERY 2009; 62:1158-1161. [PMID: 19999095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A 55-year-old man was diagnosed as having colon cancer. During the preoperative survey for metastasis, chest computed tomography (CT) revealed a well-defined tumor (33 mm) with a high CT value in the left hilum. We performed thoracoscopic resection for diagnosis and treatment. The contents of the lesion were yellowish, viscid, and creamy. Pathological examination revealed that the tumor was a bronchogenic cyst. This case is reported with a review of the literature.
Collapse
|
95
|
Kabashima Y, Kishikawa JI, Kurokawa T, Sakamoto J. Correlation Between Proton Translocation and Growth: Genetic Analysis of the Respiratory Chain of Corynebacterium glutamicum. J Biochem 2009; 146:845-55. [DOI: 10.1093/jb/mvp140] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
96
|
Nagata N, Kondo K, Kato T, Shibata Y, Okuyama Y, Ikenaga M, Tanemura H, Oba K, Nakao A, Sakamoto J, Mishima H. Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1 and 2 study. HEPATO-GASTROENTEROLOGY 2009; 56:1346-1353. [PMID: 19950789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
BACKGROUND/AIMS This study assessed the efficacy and toxicity of the FOLFOX4 (SWIFT1) and mFOLFOX6 (SWIFT2) regimens in Japanese patients with metastatic colorectal cancer (mCRC). METHODOLOGY Patients with mCRC were required to have ECOG performance status of 0 to 1, and to have adequate organ function. Two multicenter Phase II studies (SWIFT1/SWIFT2) were conducted in chemotherapy naive patients with mCRC. RESULTS 112 patients were enrolled in these studies (SWIFT1: 54 patients / SWIFT2: 58 patients). The disease sites for each study were the colon in 27 patients and 28 patients, and the rectum in 27 patients and 30 patients, respectively. All patients received a median of 8 courses. After a median follow-up period of 35 months, 54 patients and 58 patients were evaluable in the respective studies, and the overall response rate was 50.0% (CR:31 PR:53). The response rate according to the sites of metastasis were as follows: liver, 54.1% (46/85); lung, 17.4% (4/23); and lymph node, 23.3% (7/30). Grade 3/4 neutropenia occurred in 14 patients (12.5%), while Grade 3/4 non-hematological toxicities were observed in 16 patients (31.0%) and Grade 3 neurotoxicity was observed in 6patients (5.4%) and 5 patients (4.5%), respectively. CONCLUSIONS FOLFOX4 (SWIFT1) and mFOLFOX6 (SWIFT2) regimens complying with the international standard dosage and schedule can also be administered safely and effectively in Japan.
Collapse
|
97
|
Sakamoto J, Yoshino N, Okochi K, Imaizumi A, Tetsumura A, Kurohara K, Kurabayashi T. Tissue characterization of head and neck lesions using diffusion-weighted MR imaging with SPLICE. Clin Imaging 2009. [DOI: 10.1016/j.clinimag.2009.04.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
98
|
Nakayama T, Masuda N, Yamamura J, Kamigaki S, Taguchi T, Hatta M, Sakamoto J. Phase I study of combination therapy with weekly paclitaxel and cyclophosphatamide for advanced or recurrent breast cancer. Breast Cancer Res 2009. [PMCID: PMC4284903 DOI: 10.1186/bcr2300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
99
|
Hazama S, Okuyama Y, Kato T, Okayama N, Hinoda Y, Sakamoto J, Mishima H, Fujita Y, Hamamoto Y, Oka M. Use of genotype subset selections of multi-UGT1As polymorphisms to predict severe neutropenia and tumor responses of metastatic CRC patients received FOLFIRI regimen. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15038 Introduction: The pharmacogenetics of irinotecan indicate that a common polymorphism in the uridine diphosphate glucuronosyltransferase 1As (UGT1As) gene predict severe toxicity. However the tumor response to irinotecan is variable and unpredictable. Methods: Two multi-center phase II studies of FOLFIRI (FLIGHT-1 and FLIGHT-2 study) were conducted for patients with metastatic colorectal cancer (CRC) in Japan. FLIGHT-1 study was first-line chemotherapy, and FLIGHT-2 study was FOLFOX-refractory second-line chemotherapy. 103 patients have been enrolled in these studies (53 patients in FLIGHT-1 and 50 patients in FLIGHT-2) from 20 institutions by April 2007 from November 2005. Seventy one patients were analyzed UGT1As polymorphisms, UGT1A1*28 (TA6>TA7), UGT1A1*6 (G>A), UGT1A1*60 (T>C), UGT1A7 (N129K; T>G), UGT1A7 (-57 T>G), UGT1A9*22 (T10>T9). Results: Out of 71 patients, 34 had G3/4 neutropenia or leukopenia, and 23 had tumor responses (CR +PR). G3/4 neutropenia was more frequent in patients with *6, N129K(G), -57(G), *22 allele than patients without these allele (p<0.05). Other polymorphism was not the predictive factor for toxicity and tumor response, independently. On the other hand, genotype subset selection of multi-UGT1As polymorphisms was useful to predict severe toxicities and tumor responses. Only 7 patients of 22 patients with TA6/TA6 and T10/T10, or TA6/TA7 and -57(T/T), or *6(G/G) and *60(T/T) had grade3/4 toxicity. Similarly, high risk group of toxicity or high and low tumor responses groups was also predicted by genotype subset selections. Conclusions: Genotype subset selections of multi-UGT1As polymorphisms were the excellent predictor for severe toxicities and tumor responses of metastatic CRC patients received FOLFIRI regimen. No significant financial relationships to disclose.
Collapse
|
100
|
Toyooka S, Hotta K, Nakamura H, Nakata M, Tada H, Yamashita M, Watanabe N, Sakamoto J, Aoe M, Date H. A multicenter, phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): Planned interim analyses. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7560] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7560 Background: Recent studies have demonstrated that adjuvant chemotherapy provides a survival benefit in patients with resected NSCLC. In Japan, uracil-tegafur has been recognized as a standard adjuvant strategy for resected NSCLC, however, carboplatin based adjuvant chemotherapy has not been fully evaluated for the treatment of NSCLC patients in an adjuvant setting. The present phase III study assessed the efficacy and safety of carboplatin/paclitaxel and oral uracil-tegafur as the first study to compare intravenous and oral drugs in resected stage IB-IIIA NSCLC. Methods: The patients with pathological stage IB-IIIA NSCLC who underwent complete resection were randomized 1:1 to carboplatin (AUC 5) /paclitaxel (175 mg/m2) every 3 week for 4 cycles (A arm) or uracil-tegafur (250 mg/m2) daily for 2 years (B arm). The primary endpoint was overall survival (OS) and secondary endpoints were disease-free survival and toxicity. The accrual of 200 patients per arm is required to demonstrate an improvement of OS (15% increase) in the A arm compared to B arm. Randomization was stratified by histology and tumor stage. An interim analysis was planned to perform on the first 200 patients recruited and data of survival and toxicity were examined in the first 100 patients. Results: Between November 2004 and November 2008, 200 patients from 31 Japanese centers were randomized and the first 100 patients were included for interim analysis. Median age was 69 (range; 50–80) years. Ninety-eight patients had PS of 0–1 and 2 patients had PS of 2. Sixty-seven patients were male and 23 patients were female. Sixty patients had adenocarcinoma, 30 had squamous cell carcinoma, and 10 had other histologies. Disease stage was IB in 53, IIA in 14, IIB in 19, and IIIA in 14 patients. Toxicities observed during adjuvant chemotherapy were well tolerable. There was no toxic death. The median survival time of A and B arms combined was 4.1 year. Monitoring Committees approved to continue the present study. Conclusions: The present phase III trial with carboplatin/paclitaxel or uracil-tegafur is feasible with manageable toxicity. The study is on course to achieve its primary endpoint. [Table: see text]
Collapse
|